Techbio startup Antiverse has raised $9.3 million in a Series A funding round to accelerate the development of its AI-powered antibody discovery platform and expand its therapeutic pipeline.
The round saw participation from DOMiNO Ventures, Soulmates Ventures, Innovation Investment Capital, DBW, Kadmos Capital, i&i Biotech Fund, InnoSpark, and TotiPotent.
Antiverse is building an AI-native platform designed to transform how therapeutic antibodies are discovered. Traditionally, antibody development relies on lengthy laboratory experimentation and manual processes. Antiverse’s technology aims to replace this approach with a more autonomous and scalable AI-driven system capable of designing, optimizing, and validating antibodies faster and with greater precision.
The platform is designed for pharmaceutical, biotech, and medical technology companies looking to accelerate the drug discovery cycle and identify promising therapeutic candidates.
As part of its research initiatives, Antiverse has also entered into a collaboration with the Cystic Fibrosis Foundation to design antibodies targeting the extracellular region of the CFTR protein, a key component involved in cystic fibrosis and historically considered a difficult drug target.
By applying its AI-driven platform, Antiverse aims to identify and optimize new antibody candidates that could potentially lead to treatments for cystic fibrosis and other complex genetic diseases.
“We are excited to scale our AI-driven antibody design platform and accelerate our therapeutic pipeline with this Series A investment,” said Murat Tunaboylu, CEO of Antiverse. “Our collaboration with the Cystic Fibrosis Foundation is one example of how we are advancing the treatment of complex diseases with AI-powered solutions.”
The new funding will support further platform development, expansion of Antiverse’s internal therapeutic programs, and strategic collaborations with pharmaceutical and biotech partners.
Editorial Note: This article was prepared using information provided in a press release by DOMiNO Ventures.
About DOMiNO Ventures
DOMiNO Ventures is a venture capital fund focusing on high-tech, pure-digital and first-day global startups with strong origins in Eastern Europe, Central Asia and the Caucasus. We operate worldwide from offices in Amsterdam, Istanbul, London, Tallinn, Warsaw, Astana, Tashkent, Tbilisi and Baku.
The fund backs founders solving modern global challenges across sectors including AI, Deeptech, Cleantech, Healthtech, Fintech, HRtech, Edtech, Gametech, Cybersecurity, and Life Sciences, with the ambition to create a DOMiNO Effect for a Better Future.
Learn more: https://dominovc.com/
